Showing results (31-40 of 51) with videos related to
Sort By:
Pageof 6
Acta Ophthalmologica|December 16, 2020
Systemic counterregulatory response of angiopoietin-2 after aflibercept therapy for nAMD: a potential escape mechanismReinhard Angermann, Teresa Rauchegger, Yvonne Nowosielski, et al.Molecular Vision|August 25, 2012
No difference in genotype frequencies of polymorphisms of the nitric oxide pathway between Caucasian normal and high tension glaucoma patientsJohanna Weiss, Stephan A Fränkl, Josef Flammer, et al.Frontiers in Cellular and Infection Microbiology|March 19, 2024
Detection of infectious SARS-CoV-2 in ocular samples is linked to viral load in the nasopharynxJanine Kimpel, Annika Rössler, David Bante, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|November 23, 2018
Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegenerationGabriel Bsteh, Klaus Berek, Harald Hegen, et al.Brain Research Reviews|July 29, 2006
Peptidergic nerves in the eye, their source and potential pathophysiological relevanceJosef Troger, Gerhard Kieselbach, Barbara Teuchner, et al.Neurological Research and Practice|August 28, 2025
Optical coherence tomography - A possible biomarker in early huntington's diseaseClancy Cerejo, Elias Mandler, Federico Carbone, et al.Peptides|June 14, 2008
Substance P and secretoneurin in vitreous aspirates of patients with various vitreoretinal diseasesKatrin Lorenz, Josef Troger, Reiner Fischer-Colbrie, et al.BMJ Open Ophthalmology|January 12, 2022
Proton beam radiation for iris melanoma: case series and review of literatureJasmine Alexandra Hauzinger, Georgios Blatsios, Gertrud Haas, et al.Peptides|March 29, 2011
PE-11, a peptide derived from chromogranin B, in the rat eyeKatrin Lorenz, Josef Troger, Oliver Gramlich, et al.Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|April 29, 2005
Tolerability and efficacy of N-chlorotaurine in epidemic keratoconjunctivitis--a double-blind, randomized, phase-2 clinical trialBarbara Teuchner, Markus Nagl, Axel Schidlbauer, et al.Pageof 6